Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 82 (TMEM82) is a predicted multi-pass transmembrane protein encoded by the TMEM82 gene on human chromosome 1p36.21. The protein has 343 amino acids with approximately 8 predicted transmembrane domains and is highly conserved in vertebrates. TMEM82 is expressed most prominently in the kidney, liver, small intestine, stomach, and colon, particularly in specific epithelial cell types. Its expression profile and coexpression with proteins involved in lipid and xenobiotic metabolism suggest, but do not confirm, a metabolic function. No direct biochemical or pharmacological function has been experimentally demonstrated, and it is not currently considered a therapeutic target, receptor, transporter, or enzyme. Dysregulation or altered copy number at the TMEM82 locus has been associated with certain cancers (especially hepatocellular and renal cancer) and congenital urinary tract obstructions. There are no established drugs, mechanistic actions, or significant safety considerations described for this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 82 (TMEM82).